Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2023 08:01 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

Posters include data across biomarker, translation and clinical studies supportingdevelopment of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF Two posters...
March 13, 2023 08:01 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

SOUTH SAN FRANCISCO, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
March 09, 2023 16:05 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC - INTEGRIS-IPF 320 mg dose 24-week...
March 08, 2023 16:01 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
March 01, 2023 08:01 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics to Participate in Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
February 07, 2023 08:01 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics to Participate in Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
February 02, 2023 08:02 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
January 27, 2023 16:03 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
January 25, 2023 08:01 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
January 24, 2023 21:19 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...